Cargando…

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis

Introduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-López, Iciar, Maurino, Jorge, Sanmartín-Fenollera, Patricia, Ontañon-Nasarre, Ana, Santiago-Pérez, Alejandro, Moya-Carmona, Isabel, García-Collado, Carlos Gustavo, Fernández-Del Olmo, Raquel, García-Arcelay, Elena, Sarmiento, Mònica, Carreño, Ágata, Pérez-Encinas, Montserrat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356901/ https://www.ncbi.nlm.nih.gov/pubmed/32272683 http://dx.doi.org/10.3390/pharmacy8020061

Ejemplares similares

Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective
por: Meca-Lallana, José, et al.
Publicado: (2020)

Assessing Knowledge and Perceptions of Alzheimer’s Disease Among Employees of a Pharmaceutical Company in Spain: A Comparison Between Caregivers and Non-Caregivers
por: Garcia-Ribas, Guillermo, et al.
Publicado: (2020)

Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale
por: Garcia-Ribas, Guillermo, et al.
Publicado: (2021)

Burnout among neurologists caring for patients with cognitive disorders in Spain
por: Fortea, Juan, et al.
Publicado: (2023)

Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study
por: Arroyo, Rafael, et al.
Publicado: (2017)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Attitudes of Neurologists Toward the Use of Biomarkers in the Diagnosis of Early Alzheimer’s Disease
por: Fortea, Juan, et al.
Publicado: (2023)

Design of a Non-Interventional Study to Assess Neurologists’ Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease
por: Saposnik, Gustavo, et al.
Publicado: (2023)

Impacto de la pandemia COVID-19 en la formación sanitaria especializada en un centro docente
por: González-Anglada, M.I., et al.
Publicado: (2022)

Competencias esenciales en la formación de los residentes, ¿qué nos ha enseñado la pandemia por la COVID-19?
por: Anglada, María Isabel González, et al.
Publicado: (2022)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Study of Hydatidosis-Attributed Mortality in Endemic Area
por: Belhassen-García, Moncef, et al.
Publicado: (2014)

Pharmacy Student Perceptions of the Roles and Attributes of Pharmacist Preceptors in Australia
por: Knott, Gillian J., et al.
Publicado: (2022)

Episodic Past, Future, and counterfactual thinking in Relapsing-Remitting Multiple sclerosis
por: Ayala, Oscar Daniel, et al.
Publicado: (2022)

Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
por: Correale, Jorge, et al.
Publicado: (2015)

Preferences Toward Attributes of Disease-Modifying Therapies: The Role of Nurses in Multiple Sclerosis Care
por: del Río-Muñoz, Beatriz, et al.
Publicado: (2022)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Relapsing–remitting painful ophthalmoplegia due to orbital myositis
por: Guaschino, E., et al.
Publicado: (2005)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

The effect of prioritization over cognitive-motor interference in people with relapsing-remitting multiple sclerosis and healthy controls
por: Postigo-Alonso, Barbara, et al.
Publicado: (2019)

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients
por: Vázquez-Marrufo, Manuel, et al.
Publicado: (2019)

Toward an Automatic Assessment of Cognitive Dysfunction in Relapsing–Remitting Multiple Sclerosis Patients Using Eye Movement Analysis
por: García Cena, Cecilia E., et al.
Publicado: (2022)

What They Say in Remitting
Publicado: (1910)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Spinal epidural lipomatosis: An unusual cause of relapsing and remitting paraparesis
por: Rajput, Dinesh, et al.
Publicado: (2010)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8luke1pos4bhrguf3n6tj4fbht